Further, we found that high levels of phospho-AKT (p-AKT) in metastatic lesions from ER+ breast cancer patients treated with combined endocrine therapy and CDK4/6i in the advanced setting correlated with shorter PFS. This evidence concerns the gene AKT1 and breast carcinoma.